Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
The GUARD Trial is a multi-center, randomized, controlled, adaptive Phase 3 clinical trial of
repeated intravitreal injections of ADX-2191 versus standard-of-care for the prevention of
proliferative vitreoretinopathy.
Phase
Phase 3
Funding Agency/Sponsor
Industry
Disease
Retina
Enrollment Eligibility
Inclusion Criteria:
1. Subject is 18 years or older of any gender or race
2. Subject is undergoing pars plana vitrectomy due to recurrent retinal detachment due to
proliferative vitreoretionapthy or open globe injury
3. Subject is willing and able to provide written informed consent, comply with clinical
trial procedures, and return for all clinical trial visits
4. Subjects of childbearing potential must agree to use two forms of birth control for
the duration of the clinical trial
Exclusion Criteria:
1. History of severe non-proliferative or proliferative diabetic retinopathy
2. Other planned eye surgery during the course of the trial
3. Participation in a clinical trial with an investigational medicinal product or
investigational device within 90 days of subject enrollment